Alternative splicing in prostate cancer
Alternative splicing in prostate cancer, Published online: 22 August 2018; doi:10.1038/s41571-018-0085-0Androgen receptor (AR) splice variants (AR-Vs) are truncated isoforms of the AR, of which a subset remain constitutively active in the absence of circulating androgens. AR-Vs have been proposed to contribute to therapeutic resistance. The authors of this Review outline the current understanding of the role of the spliceosome in prostate cancer progression and explore the therapeutic utility of manipulating alternative splicing. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 22, 2018 Category: Cancer & Oncology Authors: Alec Paschalis Adam Sharp Jonathan C. Welti Antje Neeb Ganesh V. Raj Jun Luo Stephen R. Plymate Johann. S. de Bono Source Type: research
Economic sustainability of immune-checkpoint inhibitors: the looming threat
Economic sustainability of immune-checkpoint inhibitors: the looming threat, Published online: 20 August 2018; doi:10.1038/s41571-018-0086-zImmune-checkpoint inhibitors (ICIs) are transforming oncology, but the mounting costs of cancer care necessitate concerns regarding economic sustainability. Here, several strategies that clinicians could use to exercise economically prudent administration of ICIs are discussed. These include better appraisal of the cost-effectiveness literature, judicious patient selection, separating statistical from clinical significance, and careful patient counselling. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 20, 2018 Category: Cancer & Oncology Authors: Vivek Verma Source Type: research
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Making the first move in <i>EGFR</i>-driven or <i>ALK</i>-driven NSCLC: first-generation or next-generation TKI?, Published online: 14 August 2018; doi:10.1038/s41571-018-0081-4The clinical management of patients with non-small-cell lung carcinoma has greatly evolved owing to the development of tyrosine-kinase inhibitors (TKIs) targeted against the driver mutations of this disease. The authors of this Review describe the existing evidence on the sequential administration of TKIs and the use of next-generation TKIs upfront. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 14, 2018 Category: Cancer & Oncology Authors: Gonzalo Recondo Francesco Facchinetti Ken A. Olaussen Benjamin Besse Luc Friboulet Source Type: research
Economic comments on proposal for a novel cancer drug pricing model
Economic comments on proposal for a novel cancer drug pricing model, Published online: 13 August 2018; doi:10.1038/s41571-018-0083-2Economic comments on proposal for a novel cancer drug pricing model (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 13, 2018 Category: Cancer & Oncology Authors: Mark J. C. Nuijten Jan Vis Source Type: research
Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’
Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’, Published online: 13 August 2018; doi:10.1038/s41571-018-0084-1Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’ (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 13, 2018 Category: Cancer & Oncology Authors: Carin A. Uyl-de Groot Bob L öwenberg Source Type: research
MHC expression predicts response
MHC expression predicts response, Published online: 07 August 2018; doi:10.1038/s41571-018-0082-3MHC expression predicts response (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - August 7, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, Published online: 06 August 2018; doi:10.1038/s41571-018-0075-2Chimeric antigen receptor (CAR) T cell therapies have impressive activity in the treatment of cancer but are associated with potentially fatal toxicities. In light of the approval of CAR T cell therapy for paediatric patients, a panel of experts from the Hematopoietic Stem Cell Transplantation (HSCT) Subgroup of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, the CAR T Cell Therapy-Associated Toxicity (CARTOX) Program at The University of...
Source: Nature Clinical Practice Oncology - August 6, 2018 Category: Cancer & Oncology Authors: Kris M. Mahadeo Sajad J. Khazal Hisham Abdel-Azim Julie C. Fitzgerald Agne Taraseviciute Catherine M. Bollard Priti Tewari Christine Duncan Chani Traube David McCall Marie E. Steiner Ira M. Cheifetz Leslie E. Lehmann Rodrigo Mejia John M. Slopis Rajinder Source Type: research
Benefit of nanomedicine confirmed in sAML
Benefit of nanomedicine confirmed in sAML, Published online: 31 July 2018; doi:10.1038/s41571-018-0080-5Benefit of nanomedicine confirmed in sAML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Molecular therapies and precision medicine for hepatocellular carcinoma
Molecular therapies and precision medicine for hepatocellular carcinoma, Published online: 30 July 2018; doi:10.1038/s41571-018-0073-4Molecular profiling studies are providing novel insights into the biology of hepatocellular carcinoma, although these remain to be translated into novel effective therapies. Nevertheless, therapeutic advances have been made in the past few years, and further advancements are expected in the near future, including biomarker-driven treatments and immunotherapies, as discussed in this Review. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 30, 2018 Category: Cancer & Oncology Authors: Josep M. Llovet Robert Montal Daniela Sia Richard S. Finn Source Type: research
Immunotherapy-responsive gastric cancers identified
Immunotherapy-responsive gastric cancers identified, Published online: 30 July 2018; doi:10.1038/s41571-018-0079-yImmunotherapy-responsive gastric cancers identified (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 30, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Viruses in cancer therapy — from benchwarmers to quarterbacks
Viruses in cancer therapy — from benchwarmers to quarterbacks, Published online: 29 July 2018; doi:10.1038/s41571-018-0077-0A recent clinical trial of a virotherapy approach, consisting of an engineered poliovirus, has provided evidence of apparently durable responses in patients with recurrent glioblastoma. The results of this trial and others indicate that virotherapy might be an effective tool in anticancer immunotherapy. Yet, caution must be exercised until appropriately powered randomized clinical trials truly show efficacy. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 29, 2018 Category: Cancer & Oncology Authors: Pierpaolo Peruzzi E. Antonio Chiocca Source Type: research
Early prediction of AML risk
Early prediction of AML risk, Published online: 26 July 2018; doi:10.1038/s41571-018-0078-zEarly prediction of AML risk (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 26, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy, Published online: 26 July 2018; doi:10.1038/s41571-018-0074-3The majority of patients receiving immunotherapy do not respond to treatment but might still have adverse events. Furthermore, some patients with an initial response will develop acquired resistance to treatment. In this Review, the authors describe the role of circulating tumour DNA in the management of patients receiving immunotherapy. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 26, 2018 Category: Cancer & Oncology Authors: Luc Cabel Charlotte Proudhon Emanuela Romano Nicolas Girard Olivier Lantz Marc-Henri Stern Jean-Yves Pierga Fran çois-Clément Bidard Source Type: research
Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML
Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML, Published online: 25 July 2018; doi:10.1038/s41571-018-0076-1Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 25, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Infant medulloblastoma — learning new lessons from old strata
Infant medulloblastoma — learning new lessons from old strata, Published online: 20 July 2018; doi:10.1038/s41571-018-0071-6Comprehensive molecular characterization of infant medulloblastoma has uncovered the high degree of heterogeneity of this disease. Recent results from the SJYC07 study elegantly reveal that risk stratification can be improved if DNA methylation profiling data are incorporated into clinicopathological criteria. Importantly, the delineation of disease subgroups potentially has major clinical implications. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - July 20, 2018 Category: Cancer & Oncology Authors: Marc Remke Vijay Ramaswamy Source Type: research
